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Legislation Across the Nation
and the Impact on Pharmacy Practice
Sabrina Hamman, Hannah Lamb, Jennifer Harklerode, Elizabeth Kramer, Steven Martin, PharmD

Abstract
Pharmacy legislation is constantly being updated, g1vmg
pharmacists a larger role in the health care field. In the past
20 years, pharmacists have seen expansions to legislation
involving contraceptive authority, medical marijuana, vaccines and provider status. There is a greater pharmacist impact from legislation passed on the state level in comparison
to the national level. As a result, pharmacists have different
opportunities to provide new and advanced services to
patients based on the state in which they are practicing.
Comparing these various laws across the nation allows the
profession to determine which sections of the law are problematic and which sections are important to help advance the
profession. This information can then be used to shape new
and improved laws in other states and extend these services
to benefit more patients across the country.
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Introduction
A shortage of up to 20,000 primary care physicians is expected by the year 2020 due to the Affordable Care Act (ACA)
as well as the aging population.1 Due to this projection, it is
becoming vital for other health care professionals to provide
basic primary care services that were otherwise reserved
for physicians. Although the increasing number of certified
nurse practitioners and physician assistants has benefitted
the health system, there is still a high demand for additional
primary care resources. This primary care shortage along
with the education and knowledge base of doctoral pharmacists are possible reasons why the scope of pharmacy
practice continues to broaden in many states. In an effort to
increase patient access to care, new legislation has been
enacted to build upon the pharmacist's immunization certification and increase involvement in contraceptive prescribing
and medical marijuana dispensing. Additionally, pharmacists
are advocating for provider status, meaning that their services would be included under Medicare Part B coverage. If
such legislation would pass, new payer models would develop to sustain available services such as medication therapy
management (MTM) and create incentives to provide additional primary health services.
Provider Status
Pharmacists have a unique skill set that could greatly benefit
a health care team.2 Medication nonadherence and uncontrolled chronic disease states can lead to excess or unnecessary hospital stays, which are easily avoidable if the right
patient education is provided. Pharmacists are able to pro-
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vide the proper patient counseling on medications, disease
state management and the prevention of diseases. This ability would be a great asset to the health care team. Pharmacist
involvement has been shown in studies and practice-based
experience to improve patient outcomes, increase patient
satisfaction rates and reduce the overall cost of health care.
Pharmacists have the potential to play a much larger health
care role in the United States.3 Currently, the U.S. health care
system faces challenges with the increasing need for health
care access, the demanding quality of this care and excessive
costs. In 2002, the Medicare Payment Advisory Commission
(MedPAC) stated there was increasing evidence that pharmacists taking a more active role in managing drug treatment
could reduce costs and improve the quality of patient care.
Since then, the profession has progressed, but there are still
many opportunities for pharmacists to become more involved and become recognized health care providers.
The House of Representatives bill H.R. 592 and Senate bill
S. 314 are two important federal bills introduced into Congress during the 114th Congress that would amend the Social
Security Act, specifically Medicare Part B, to allow pharmacists to receive compensation for their services in medically
underserved areas. 4.s Pharmacists would receive reimbursement at a rate of 80 to 85 percent of what a physician providing the service would receive. These bills have continued to
gain support from legislatures, but face opposition due to the
initial costs of providing the service. The initial costs are because of pharmacists billing for their time. Evidence is needed to show that there is a long-term, overall reduction in cost
to the health care system due to decreased admission rates,
physician visits and better patient outcomes.
A literature review done by Ponniah and colleagues looked at
seven studies evaluating outpatient and post-discharge pharmacy services' impact on patients with heart failure.6 Six of
the seven studies found positive outcomes for patients such
as decreases in readmission rates, mortality and greater
compliance with medication regimens. Another study did not
show a difference between the control group and interventional group.13 This review demonstrated the importance of
pharmacist involvement in the continuity of care. The expansion of these types of services could lead to better care and
outcomes for patients.
Without provider status recognition and a payment model
for pharmacist services, such as pharmacist-initiated smoking cessation therapy, contraceptive services or diabetic shoe
fittings, providing them may not be sustainable and, thus,
they become less accessible to patients.2 Having reimburse-
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ment in place would incentivize employers to provide these
services, which would increase access to care. Pharmacists
would be given the chance to innovate and create new practice models to better serve patients and improve the quality
of care and patient outcomes.

Provider Status in Ohio
In Ohio, a recent project has produced data showing the benefit of pharmacist intervention in patients with diabetes and
hypertension.14 With the help of a grant from the Centers for
Disease Control and Prevention (CDC), in 2014 three federally qualified health centers (FQHCs) in Ohio partnered with
the Ohio Department of Health (OOH) in order to test the
outcomes of pharmacists providing medication therapy management (MTM) to patients with diabetes and hypertension.
The FQHCs monitored patientAlC and blood pressure before
and after the MTM services were provided to analyze the
benefit of extra pharmacist intervention.
The data from over 500 patients in a six month period
showed an increase in diabetes control from 0 to 44.8 percent and hypertension control from 0 to 68.6 percent.14 This
project will continue by adding more FQHC sites and some
primary care physician practices. Hopefully, showing the
benefit of these MTM services will increase payer support for
them in the future.

Pharmacists and Contraceptive Authority
The Problem
According to Santelli and colleagues, unintended pregnancies are defined as being either unwanted or mistimed. ls In
2012, 40 percent of all pregnancies worldwide were considered unintended, despite the wide variety of available
contraceptives. 1 6 Unintended pregnancies have been associated with poor health, financial and social outcomes for
both mothers and children, creating a worldwide disparity
in this population. In the United States, it is estimated that
82 percent of all teenage pregnancies are unintended.17
While the rate of teenage pregnancy in the United States
has been declining in recent years, the country still has the
highest rate among other similarly developed countries.
Access to care, societal stigmas, socioeconomic imbalance
and sexual behavior are all expected to be reasons for this
statistical gap.
Unintended pregnancies in the United States have the highest rates among 18 to 24 year olds, minorities and low education and/or low income women which costs the U.S. health
care system a significant amount of money.10 According to
the Guttmacher Institute, $21 billion was spent in 2010 on
unintended pregnancies nationwide. However, many methods have been shown to help reduce this cost. One method is
family planning. Women who used contraceptives correctly
only accounted for 5 percent of total unintended pregnancies. Therefore, increasing access to contraceptive methods
has the potential to decrease the rate of unintended pregnancies in the United States and would most likely reduce public
expenditures over time.
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Current Legislative Actions
Currently in order to obtain contraception, most women
must visit a physician or go to a women's health clinic.19 This
can be difficult for many reasons: women may not be able to
get time off from work, physicians may not have immediate
openings to see the patient or a patient may lack the insurance needed to see a physician. Visiting a pharmacist may
alleviate these complications since pharmacists are one of
the most accessible health care professionals. In fact, 93 percent of people in the United States live within five miles of a
community pharmacy.20 In order to help improve access to
contraceptive care in their respective states, California and
Oregon recently passed laws allowing pharmacists to prescribe hormonal contraceptives.21,22 Tennessee's senate bill
S.B. 1677 with similar provisions has also been recently
passed.23 While California passed the law earlier than Oregon,
Oregon is the first state to implement it as of Jan. 1, 2016.
The Oregon law, house bill (H.B.) 2879, allows pharmacists
who have taken a board-approved training course to prescribe hormonal contraception in the form of an oral tablet
or patch to a patient over 18 years of age or patients under
18 years of age with previous evidence of a prescription from
a health care practitioner.24 Before the pharmacist prescribes, they are required to have the patient complete a selfscreening risk assessment tool, which includes questions
about a patient's sexual and medical history.zs This selfscreening risk assessment tool then helps the pharmacist
decide whether or not a patient is eligible for pharmacistinitiated contraception or if the patient should be referred
for further evaluation by a primary health care provider or a
woman's health care provider.26 If the pharmacist determines contraception is appropriate, the pharmacist must
then refer the patient to a primary health care provider and
provide a summary of the initial visit. This is done in order to
promote communication between the patient and their
health care providers, help them find a health care provider
if they do not have one and promote additional routine
health screenings. Furthermore, the pharmacist cannot continue to prescribe the medication if the patient does not have
a clinical visit with a health care provider within three years
of the first prescription.24 A clinical visit is defined as a consultation addressing appropriate women's health screenings
and contraception by a health care provider other than a
pharmacist.21 See Figure 1 and Figure 2.2s,26
In addition to the passing of H.B. 2879, Oregon has also
passed H.B. 3343. This law requires insurance companies to
allow patients to receive a 12-month supply of a birth control
medication or device.27 This law will also help with women's
access to contraceptive care regardless of who provided the
prescription. Allowing a patient to receive all 12 months at
once may improve adherence which may lead to better outcomes for the patient.28 This expanded access is not expected
to decrease women's likelihood of receiving regular preventive care screenings.29

Support and Opposition
There is controversy regarding a pharmacist's ability to pro-

THE PHARMACY AND WELLNESS REVIEW

27

Legislation Across the Nation and the Impact on Pharmacy Practice

Legislation

Figure 1 . Hormonal Contraceptive Self-Screening Questionnaire.

Hormonal Contraceptive Self-Screening Questionnaire
Name
Health Care Provider's Name - -- - -- - -Date_ _ __
Date of Birth
Age*
Weight
Do you have health insurance? Yes/ No
What was the date of your last women's health clinical visit?
Any Allergies to Medications? Yes I No If yes, list them here:

Background Information:
-

Do you think you might be pregnant now?
What was the first day of your last menstrual period?
Have you ever taken birth control pills, or used a birth control patch, ring, or
shot/injection?
Did you ever experience a bad reaction to using hormonal birth control?
- If yes, what kind of reaction occurred?
Are you currently using any method of birth control including pills, or a birth control
patch, ring or shot/injection?
- If yes, which one do you use?
Have you ever been told by a medical professional not to take hormones?
Do you smoke cigarettes?

2
3

4

s

Yes o
Yes o

Noo

Yes o

Noo

Yes o

Noo

Yes o
Yes o

Noo
Noo

Have you given birth within the past 6 weeks?
Are you currently breastfeeding?

Yes o
Yes o

Noo
Noo

Do you have diabetes?
Do you get migraine headaches? If so, have you ever had these kinds of headaches
that start with warning signs or symptoms, such as flashes of light, blind spots, or
tingling in your hand or face that comes and goes completely away before the
headache starts?
Do you have high blood pressure , hypertension, or high cholesterol?
Have you ever had a heart attack or stroke, or been told you had any heart disease?
Have you ever had a blood clot?
Have you ever been told by a medical professional that you are at risk of developing a
blood clot?
Have you had recent major surgery or are you planning to have surgery in the next 4
weeks?
Have you had bariatric surgery or stomach reduction surgery?
Do you have or have you ever had breast cancer?
Do you have or have you ever had hepatitis, liver disease, liver cancer, or gall bladder
disease, or do you have jaundice (yellow skin or eyes)?
Do you have lupus, rheumatoid arthritis, or any blood disorders?
Do you take medication for seizures, tuberculosis (TB), fungal infections, or human
immunodeficiency virus (HIV)?
- If yes, list them here:

Yes o
Yes o

Noo
Noo

Yes o
Yes o
Yeso
Yes o

Noo
Nao
Noo
Nao

Yes o

Noo

Yes o
Yeso
Yes o

Noo
Noo
Noo

Yes o
Yes o

Noo
Nao

Yes o

Noo

I

Medical History:

6
7

8
9

-

11

12
13
14

15

16

19

20

Noo

Do you have any other medical problems or take any medications, including herbs or
supplements?
- If yes, list them here:

-

_}_/_

-

-

Do you have a preferred method of birth control that you would like to use?

o A pill you take each day o A patch that you change weekly o
Internal use only
Pharmacist Name
0 Drug Prescribed
Sig:
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Other (ring, injectable, implant, or IUD)

D verified DOB* with valid photo ID D BP Reading --~ _ __
Rx#
(Pharmacy Phone

Pharmacist Signature---- - - - - - - - -or- 0Patient Referred-circle reason(s)
Address
)
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Figure 2 . Standard Procedures Algorithm for Oregon Pharmacist Prescribing of Contraceptives.

STANDARD PROCEDURES ALGORITHM FOR OREGON RPH PRESCRIBING OF CONTRACEPTIVES
1) Health and History Screen
Review Hormonal Contraceptive Self-Screening Questionnaire.
To evaluate health and history, refer to USM EC or Oregon MEC.
1 or 2 (green boxes} - Hormonal contraception is indicated, proceed to next step.
3 or 4 (red boxes} - Hormonal cont raception is contraindicated --> Refer

•

I

....---

( Contraindicating
Condition(s)

r

-

)

No Contraindicating Conditions

::a
C'D
;;'
.....

....

2} Pregnancy Screen
a. Did you have a baby less than 6 months ago, are you fully or nearly-fully breast feeding, AND have you had no
menstrual period since the delivery?
b. Have you had a baby in the last 4 weeks?
c. Did you have a miscarriage or abortion in the last 7 days?
d. Did your last menstrual period start within the past 7 days?
e. Have you abstained from sexual intercourse since your last menstrual period or delivery?
f. Have you been using a reliable contraceptive method consistently and correctly?

[

]

Possible
Pregnancy

....---

::a

.....

,

C'D

;;'
.....

-

If YES to AT LEAST ONE and is free of pregnancy symptoms, proceed to next step.
If NO to ALL of these questions, pregnancy can NOT be ruled out-> Refer

~

I

I

Patient is not pregnant

3) Medication Screen {Questionnaire #20)?
Caution: anticonvulsants, antiretrovirals, antimicrobials, barbiturates, herbs & supplements, including:
carbamazepine
oxcarbazepine
rifampin I rifabutin
phenobarbital
felbamate
ritonavir
phenytoin
griseofulvin
St. Johns Wort
primidone
topiramate
lamotrigine

-

[ Contraindicating
Medications

::a
C'D
;;'
.....

~

,

~

i

I

No Contraindicating Medications

I

(

4) Blood Pressure Screen:
Is blood pressure <140/90?
Note: RPH may choose to take a second reading, if initial is high.

! I

BP >140/90

)

~

r

BP<

I

140/90

::a
C'D
;;'
.....

.....__

5) Evaluate patient history, preference, and current therapy for selection of treatment.

I

Not currently on birth control

I

/'\.!

Sa) Choose Contraception
Initiate contraception based on patient
preferences, adherence, and history for
new therapy
-Prescribe up to 12 months of desired
contraception and dispense product
(quantity based on professional judgment and
patient preference)

Patient is currently on birth control

I

Sb) Choose Contraception
Continue current form of pills or patch, if no change is necessary
-orAlter therapy based on patient concerns, such as side effects patient
may be experiencing; or refer, if appropriate
-Prescribe up to 12 months of desired contraception and dispense
product. (quantity based on professional judgment and patient preference)

+

'+'

6) Discuss Initiation Strategy for Initial Treatment/Change in Treatment (as applicable)

a) Counseling- Quick start- Instruct patient she can begin contraceptive today; use backup method for 7 days.
b) Counseling - Discuss the management and expectations of side effects {bleeding irregularities, etc.)
c) Counseling - Discuss adherence and expectations for follow-up visits

'+'
7) Discuss and Provide Referral I Visit Summary to patient
Encourage: Routine health screenings, STD prevention, and notification to care provider
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vide this service with adequate monitoring and follow up and
if this is the best way to improve access for women.19,30,31 The
American College of Obstetricians and Gynecologists (ACOG)
released a statement claiming that while they approve of allowing pharmacists to prescribe birth control, they still ultimately want contraception available over-the-counter
(OTC).31
Although many providers support pharmacist-initiated
contraception, some have argued that pharmacists are still
another barrier for women to go through to receive contraceptives.19,32 Rafie and colleagues evaluated provider opinions on prescription-only, pharmacist-initiated, behind the
counter versus OTC contraceptives.32The investigators in the
study surveyed 614 health care providers from different
areas around the United States on various topics surrounding birth control access. The study found that 74 percent of
providers supported pharmacist-initiated access for the pill,
patch and vaginal ring. The study also found that while
45 percent supported behind the counter access, 28 percent
of providers supported OTC availability of the same dosage
forms. There have been studies conducted that have shown
that women can accurately screen themselves for eligibility
for birth control if given the right tooJ.33,34 However, this may
!eave the patient with limited monitoring by a health care professional. Insurance companies also may not pay for OTC contraceptives. This would be an additional barrier for women.
While pharmacist-initiated contraceptives would significantly improve access for patients, providers have the concern
that too few pharmacies would participate in the service,
constituting a barrier to patient access.32 Without proper
reimbursement models for pharmacist services, it may be
hard to justify the extra training required along with the time
needed for pharmacists to provide these services. Legislation
is needed to address this issue.

Pharmacist Qualification
In order to become a pharmacist, one must complete at least
six years of training after high school in order to obtain a
Doctor of Pharmacy (PharmD) degree.3 During this training,
pharmacists learn pathophysiology, pharmacotherapy and
disease state management, as well as a variety of other skills
such as preventive screenings, point-of-care testing and basic
physical examination. Pharmacists are medication experts
and are able to manage possible drug interactions with birth
control and interpret screening results to determine the appropriateness of contraceptive therapy.35
Studies have shown that pharmacist-initiated contraception
is safe and effective.35 Gardner and colleagues conducted a
study that examined 214 women ages 18 years to 44 years
who consulted pharmacists for contraceptive care. Over half
the participants reported having a provider they regularly
saw for primary care. Most patients participated in the study
due to the convenience of having a pharmacist-prescribed
contraceptive. In addition, many patients stated that they did
not want to receive a pelvic exam before initiating contraceptives.

30

Before the prescription was provided, patients completed a
screening tool to determine if they were able to use hormonal contraceptives safely along with a blood pressure check
and weight check.35 Pharmacists then consulted with patients on their eligibility to receive pharmacist-initiated contraceptives. Patients had to have a blood pressure of less
than 140/90 mmHg and a weight less than 200 pounds in
order to be eligible for pharmacist-initiated contraception. If
patients did not meet these criteria, they were referred to a
family planning clinic for further evaluation. Patients that
were eligible then received a prescription and were required
to return to the pharmacy again after three months for a second blood pressure and weight check. In addition, phone interviews were conducted at one month, six months and 12
months by the study interviewers to assess patient satisfaction with their interactions and hormonal contraceptive
choice.
At the 12 month interview, 70 percent of eligible participants

reported continued use of their contraception.35 Of these,
98.6 percent (123 out of 127) of women reported that they
would feel comfortable continuing to receive contraception
from a pharmacist. Some patients were lost due to lack of
follow up, occurrence of adverse events and dissatisfaction
with their prescribed contraceptive method. There were limitations to this study due to conservative prescribing requirements for patient eligibility. In addition, women under
the age of 18 years were not included and, due to the lack of
insurance reimbursement, many patients had to pay out-ofpocket for the cost of these services. Therefore, many lowincome women could not afford to participate in the study.
However, it was advantageous for uninsured women to
enroll since pharmacist services in general were much less
expensive than physician services. While there may be limitations, this study helped show effectiveness of pharmacistinitiated contraception.
Pharmacists remain a largely untapped resource for contraceptive services across the nation. With the implementation
of new laws in Oregon and California, more data may become
available over time to show the benefit of the expansion of
pharmacist services. Depending on the outcomes, other
states may follow suit. This could be a new area of practice
for pharmacists to play a role in women's health and improve
access to care.

Legalization of Medical Marijuana
The legalization of marijuana, or cannabis, is not a new debate and has been an upcoming issue in recent years. The
question of legalizing marijuana for medical or recreational
use or both is an issue that presses current legislation. One of
the reasons for the push to legalize medical marijuana is due
to its pharmacologic effects and the potential medical
benefits it can provide to patients. Marijuana has at least 460
active chemicals and 60 different cannabinoids (CBD), with
8-9-tetrahydrocannabinol (THC) being the predominant cannabinoid that is responsible for the pharmacologic effects by
binding to either of the two receptor subtypes.36,37 The cannabinoid-1 receptors (CBl) are located predominantly in the
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central nervous system including the cortex, hippocampus,
basal ganglia, cerebellum and spinal cord. The cannabinoid-2
receptors (C82) are located mostly in the peripheral tissues
on cells responsible for an immune response.
Many chronic disease states may benefit from the use of
medical marijuana including multiple sclerosis, pain syndromes and glaucoma.36 It can also help alleviate nausea and
vomiting associated with chemotherapy treatment, as well as
reduce weight loss due to the disease progression of cancer
or HIV. While there are various studies that demonstrate
the efficacy of this product for a wide variety of disease
states,37·42 many of these studies are case studies or trials
with small sample sizes and caution should be taken when
interpreting these results for an entire population of patients.
Mahmoud E!Sohly, Ph.D., research professor at the University
of Mississippi School of Pharmacy and director of the
University of Mississippi Marijuana Project brings up another
concern with medical marijuana dosing.43 The University of
Mississippi has the only federally funded marijuana research
program in the country and has yet to determine the appropriate dose, frequency or duration of treatment for the use of
marijuana in any disease state. This lack of data can pose
problems when trying to provide marijuana as a mode of
treatment.
Pharmacist Role and Reactions
Many pharmacists are concerned with the state-level legalization of medical marijuana in fear that it might jeopardize
their license and career since it is still illegal to distribute this
drug under federal law.43 Others have expressed concern

Legislation

because they feel that they do not have the proper education
and training to be dispensing medical marijuana to their patients. Providing proper education to pharmacists will be key
to helping them feel more confident with dispensing this
product. Dispensing medical marijuana would allow pharmacists to expand their title as a drug and medication expert by
helping to monitor patient use to ensure the drug is being
used in a safe and effective manner. According to the American Pharmacists Association (APhA) 2015 report from the
house of delegates, the policy pertaining to the role of pharmacists when caring for patients using cannabis contains five
key aspects. The APhA supports furthering clinical research
to establish the clinical efficacy and safety of the use of cannabis, encourage further health care provider education and
advocate that pharmacists collect and document all patient
information regarding cannabis use. This policy also supports the role of the pharmacist to dispense cannabis to patients when it is scientifically supported and the proper laws
are in place while countering pharmacists from becoming a
provider of cannabis for recreational purposes.
There are many drugs and disease states that have potential
interactions with medical marijuana.36 A pharmacist can
have a large impact on patient safety by checking for any
drug-drug or drug-disease interactions while also monitoring
the patient closely for any adverse reactions.
Current State Versus Federal Legislation
The legalization of marijuana for medical purposes was accomplished by individual states passing their own legislation
to remove the criminal actions taken against a patient for
possession of the drug. However, federally, the Controlled
Substances Act (CSA) classifies marijuana as a Schedule I

Table 1. Medical Marijuana and Drug Interactions.36,44-48
Drug
Opioids

Possible Interactions
Cross-tolerance, mutual potentiation of effect

Benzodiazepines
Muscle relaxants
Lithium
Opioids
Alcohol

Excessive CNS depression
Drowsiness

Anticholinergics
Alpha-agonists

Tachycardia
Exacerbate hypertension

Naltrexone

Increased effects of euphoria

Disulfiram

Hypomanic episodes

Sildenafil

Myocardial infarctions

Fluoxetine

Mania

Tricyclic antidepressants

Tachycardia
Delirium
Spring 2016 Volume 7, Issue 2 THE PHARMACY AND WELLNESS REVIEW
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Table 2. Medical Marijuana and Disease State lnteractions.36,49-S4
Possible Interactions

Disease State
HIV
Diabetes
Lupus
Rheumatoid arthritis
Cancer
Organ transplantation
Schizophrenia
Psychosis
Bipolar disorder
Depression
Eating disorders
Cardiovascular disease

Increased health risk due to increased immunosuppressive properties

Exacerbation of respective psychiatric disorder
Four times as likely to develop depression
Increased hallucinations, delusions and violent behavior

Increased risk of effects (stroke, myocardial infarction)

COPD
Asthma
Tuberculosis

Increased risk with long-term marijuana use

Vertigo

Increased dizziness
Complications with diagnosis and treatment

Diabetes
Obesity
Pregnancy

Significant, undesirable weight gain
Impaired fetus development
Structural and neurobehavioral defects in the fetus

which defines it as a drug that has a high potential for abuse,
no acceptable medical use and a lack of accepted safety when
using this drug under medical supervision.ss When state and
federal laws conflict, the stricter law is typically enforced,
meaning that all possession of marijuana for medical purposes, regardless if legal in the state, is still illegal. However, only
1 percent of convictions that involve marijuana are federal
cases, making it highly unlikely for a patient to be federally
convicted for using medical marijuana. 56
Current and Future Legislation
As of April 2016, there are four states along with the District
of Columbia that have legalized the use of both medicinal and
recreational marijuana, as depicted in Figure 3.S7,S8 An additional 20 states have legalized marijuana strictly for medical
use, and another 17 states have passed limited access marijuana product laws which allow for the use of products with
low THC and high CBD levels for selected medical purposes.
Each of these states is unique in the laws that they have
passed in regard to the legal implications for the use of marijuana. Adoption of legislation related to marijuana use and
distribution is occurring rapidly and several changes may be
in place by the time of this publication. The information used
to populate Figure 3 was obtained from two sites that are
updated regularly.57,58 These sites may be accessed for more
up-to-date information.

32

California
California was the first state to legalize the use of medical
marijuana with Proposition 215, also known as the Compassionate Use Act of 1996.s7,s9 The Compassionate Use Act was
passed to allow medical marijuana to be prescribed to patients with any disease state that may benefit from its use.s9
This law also ensures that prescribing physicians and patients using marijuana for medical purposes will not be subject to criminal punishment. Seven years later, the state of
California passed SB 420. This additional law allowed for
better identification of patients and their primary caregivers
in order to eliminate unnecessary arrests, enforcement of
uniform enactment of the laws by different counties across
the state and further enhanced patient access to medical marijuana.60
Since California was the first state to pass medical marijuana
laws, it provides a legislative model for other states. Some
proposed changes for future states include strictly defining
the disease states that patients may have in order to have
access to medical marijuana and limiting the number of dispensaries.61 This will ensure that medical marijuana use is
only for patients who have disease states where proven benefits of its use exist. Placing restrictions on the number of
dispensaries will help ensure the highest quality and standards for marijuana products while limiting the risk of illegal
dispensing.
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Connecticut
In April 2012, Connecticut passed HB 5389 to allow for the
use of medical marijuana.62 This legislation is similar to California; however, there are some differences in how the legislation was phrased. First, the law states that a person is eligible to use marijuana for a medical purpose if they have a
"debilitating medical condition." These conditions include
cancer, glaucoma, HIV/AIDS, posttraumatic stress disorder,
Parkinson's disease, multiple sclerosis, damage to the nervous tissue of the spinal cord, epilepsy, cachexia, wasting syndrome and Crohn's disease. Additionally, if a person with a
different condition feels like he or she could benefit from
medical marijuana treatment, it must be approved by the
Department of Consumer Protection (DCP). This specific
wording excludes marijuana use in the treatment of other
diseases that is managed efficiently by other prescription
medications.

Additionally, legalizing medicinal marijuana in this state led
to the Connecticut Prescription Monitoring and Reporting
System in which both pharmacists and physicians have access.63 This law will protect patients, caregivers, physicians
and dispensaries from criminal action for the possession or
use of medical marijuana within the scope of its legislation.62

Patient certification from a prescriber that states that the
patient has a chronic disease constituting medical marijuana
use is also included in HB 5389.62 This certification must be a
DCP-prescribed form with the physician's signature and date
and is valid for up to one year. HB 5389 also limits the number of dispensaries in the state. The DCP commissioner determines the number of dispensaries needed to meet the
needs of patients that qualify to receive medical marijuana.

Mississippi
In April of 2014, Mississippi signed HB 1231, or Harper
Grace's Law. 64 This legislation allowed patients with debilitating epileptic conditions and their caregivers to have possession of marijuan;:i extracts, oils or resins containing more
than 15 percent of CBD and no more than 0.5 percent THC.
While this law is beneficial to those with epileptic conditions,
access to this product is very limited. The National Center for

One aspect that is unique to Connecticut law is that only a
licensed pharmacist is eligible to apply for and receive a dispensary license. This may have helped the bill pass, as it provides more medically driven regulation for patients.63 As of
June 2015, there are six dispensaries in Connecticut, with
four owned by pharmacists. Connecticut legislation provides
new opportunities for pharmacists to exercise both their entrepreneurial skill set by owning dispensaries and utilizing
their clinical skills in selecting and dosing the right product
for the patient.

Figure 3. Marijuana Laws by State.57,58
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Natural Products Research at the University of Mississippi is
the only location that can produce this oil. Furthermore, the
Department of Pharmacy Services at the University of Mississippi Medical Center is the only place that can dispense the
product. While Mississippi is the only state with federal privileges to produce marijuana products, it still prohibits distribution to patients, as well as the actual use of the drug, despite state legislation. On Feb. 8, 2016, HB 1360 and SB 2358
were introduced in an effort to legalize medical marijuana in
the state of Mississippi.65 Both pieces of legislation, however,
died in committee later that month.
Ohio
Ohio has recently joined other states in the passage of a medical marijuana bill. In November 2015, Issue 3: The Ohio Marijuana Legalization lnitiative, was on the ballot.66 Issue 3
proposed the legalization of the production and sale of both
medical and recreational marijuana and included provisions
for a monopoly for only select individuals to participate. This
would have allowed persons over the age of 21 years to possess up to one ounce of marijuana for recreational use and
grant anyone with medical certificate permission for medical
use. However, nearly 64 percent of Ohioans voted against
Issue 3. The state General Assembly subsequently passed
HB 523 and, in June 2016, the governor signed this legislation to allow for medical marijuana only.5 7,66,67 At this time, it
has not yet become operational.
The two main differences between the original proposed legislation and the current legislation is HB 523 does not allow
for the home growing of marijuana and does not require employers to allow employees to use medical marijuana.57,68,69
Immunization Laws
Pharmacist Impact on Disease Prevention
Pharmacists have the potential to make a drastic impact on
disease prevention by being involved with providing vaccinations across the country.10 A study conducted by Goad and
colleagues found that 30 percent of vaccinations given at a
community pharmacy during the 11 month study period
were provided during off-clinic hours.71 These hours consisted of weekday evenings, weekends and federal holidays
when a physician's office, where patients would traditionally
receive a vaccine, is closed. This time period was exceptionally popular with younger, working-aged, healthy adults. With
a pharmacist's ability to administer vaccinations, community
pharmacies are able to create new opportunities to increase
the low immunization rates that are observed in the adult
and adolescent age groups. This can be done by expanding
access and convenience to vaccinations to better suit the lifestyles of this age group. Additionally, it has been found that
the immunization rates, specifically for the influenza vaccine,
in states that allow pharmacists to administer vaccines is
higher than in states that do not allow this.n With this trend,
it is suggested that pharmacists are not pulling patient populations away from medical centers but are instead bringing in
new populations to receive vaccinations. Regarding the benefits of immunizations, it has been shown that vaccinations
specifically against influenza lead to a reduction in the rates
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of hospitalization and deaths from influenza related complications when compared to unvaccinated groups.73 This is
especially true in elderly populations. Additionally, a cost
benefit model was created by Duncan and colleagues to show
the overall savings related to the implementation of a vaccination program within a company. 74 It was found that if a
company was to have at least SO percent of employees vaccinated at a pharmacy, there would be an employer cost savings of $49 per vaccination.
Increasing both the accessibility to pharmacists who are already able to vaccinate, as well as the types of vaccinations
pharmacists are able to administer, will allow for increased
rates of disease prevention. This will also lead to a decreased
overall cost to the health care system. In order for legislation
to be drafted and passed across the country, more detailed
studies are needed to solidify the benefits of pharmacists
administering vaccinations.
CDC Recommendations
As of January 2015, pharmacists were able to administer any
Centers for Disease Control and Prevention Advisory Committee for Immunization Practices (CDC ACJP) approved vaccine in 45 states, excluding New Hampshire, Florida, New
York, West Virginia and Wyoming.7s Ohio was added to this
list in March 2015. Age restrictions, as well as prescription
protocols, vary from state to state for each CDC ACIP vaccination.
Vaccinations currently recommended by the CDC for adults
aged 19 years or older are shown in Figure 4.76 If a patient is
younger than 19 years of age, or has any other medical conditions, consult a physician before administering any vaccinations.
Vaccine Legislation Across the United States
Immunization laws and regulations greatly vary between
states across the nation. In many of these states, a prescription is required to receive a vaccine from a pharmacist.75 The
state of New Hampshire has a more limited scope of immunization laws than states that require a prescription. On Aug.
26, 2011, Senate Bill 93 expanded the vaccines a pharmacist
could administer and the qualifications needed in the state.77
Currently, pharmacists can administer the influenza, pneumococcal, and varicella zoster vaccines. They must then notify the patient's primary care provider, when asked by the
patient, after administering the pneumococcal and/or varicella zoster vaccines. Pharmacists also must hold a current
license and have completed training specific to the vaccination being administered.
Additionally, pharmacists in all 52 states and territories
of the United States have the authority to administer the
pneumococcal part B vaccine and the zoster vaccine.75 Other
vaccines, such as tetanus-diphtheria or tetanus-diphtheriapertussis (Td/Tdap), human papillomavirus (HPV) and
meningococcal, can be administered by pharmacists in most
circumstances, but a few states still pose restrictions (Table
3).
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Figure 4. CDC Recommended Vaccinations for Adults 19 years of age or older - 2016. 76
VACCINE

AGE

Influenza

~

19 years

1 dose annually

Tetanus, diphtheria, pertussis (Td/
Tdap)

~

19 years

Substitute Tdap for Td once, then Td
booster every 10 years

Varicella

;:: 19 years

2 doses

Human papillomavirus (HPV)

19-26 years (females)
19-21 years (males)
22-26 years (males with a risk factor)

3 doses

Zoster

;:: 60 years

1 dose

Measles, mumps, rubella (MMR)

19 years - anyone born after 1956

1 or 2 doses depending on indication

Pneumococcal 13-valent conjugate
(PCV13)

19 - 65 years with risk factors
;:: 65 years

1 dose

19 - 65 years with risk factors

1 or 2 doses based on indication

;:: 65 years

1 dose

Pneumococcal 23-valent polysaccharide
(PPSV23)

DOSE

Hepatitis A

<::

19 years with risk factors

2 or 3 doses depending on vaccine

Hepatitis 8

<::

19 years with risk factors

3 doses

Meningococcal 4-valent conjugate
(MenACWY) or polysaccharide (MPSV4)

<::

19 years with risk factors

1 or more doses depending on indicati on

Meningococcal 8 (MenB)

;:: 19 years with risk factors

Haemophilus influenza type 8

<::

19 years with risk factors

2 or 3 doses depending on vaccine
1 or 3 doses depending on indication

Table 3: States and Territories Where Pharmacists Cannot Administer Various Vacccines.75

Vaccine

U.S. States/ Territories Where Pharmacists Cannot
Administer Specific Vaccines

Tetanus-Diphtheria or Tetanus-DiphtheriaPertussis (Td/Tdap)

Florida, New Hampshire, New York

HPV vaccination

Florida, New Hampshire, New York, West Virginia

Meningococcal vaccine

New Hampshire, West Virginia
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Figure 5 was adapted from data collected by APhA. 7s The
figure illustrates the number of states and territories in
which a pharmacist can administer the listed vaccination,
starting with an age within the listed range.

Pharmacy Profession Recommendations
States with expanded immunization authority for pharmacists each have their own training requirements that must be
completed. The American Society of Health-System Pharmacists (ASHP) suggests that a training program should include:70
• Education on the at-risk patient populations as well as
public health goals.
• Vaccine safety.
• Contraindications and precautions of vaccinations.
• Stability and storage of vaccinations.
• Drug interactions.
• Vaccine dosing, including immunization schedules.
• Proper dose preparation and injection technique.
• Signs and symptoms of adverse reactions, reporting of
these and emergency procedures.
• Documentation and reporting to primary care provider
and/or local health department.
• Billing information.
Pharmacy interns are currently able to administer
vaccinations in 44 states and territories based on state laws
surveyed effective Jan. 11, 2014.75 In these states and territories, interns are required to complete a certificate training
program as well as operate under the supervision of a
trained pharmacist at all times. States and territories in
which interns may not administer vaccines as of this writing
are Florida, Massachusetts, New Hampshire, New Jersey,
New York, Pennsylvania, Puerto Rico and South Carolina.

How Ohio Compares
Currently in the state of Ohio, pharmacists and pharmacy
interns working under the direct supervision of a pharmacist
can administer any vaccination recommended by the CDC
ACIP to individuals 13 years old and older without a prescription.78 Additionally, they can vaccinate patients 7 to 13
years old with a prescription. Influenza vaccinations can be
given to those 7 years and older without a prescription. Before administering vaccinations, the pharmacist or pharmacy
intern must successfully complete immunization training
which aligns with the standards set forth by ASHP.
As more states begin to follow suit and pass legislation to
allow pharmacists to provide vaccinations, the country as a
whole will be positively impacted and public health across
the nation will likely improve.

Conclusion
As legislation expanding the pharmacists' scope of practice
continues to be introduced on a state level, access to health
care will continue to grow. Pharmacists are seeing expansions in their roles regarding contraceptive authority, dispensing of medical marijuana and providing immunizations.
This expansion helps pharmacists to accommodate the shortage of primary care physicians, resulting in better patient
care. At a national level, provider status will help compensate
pharmacists for some of the services they may already be
providing, in addition to future patient care initiatives. With
progressive legislative initiatives, pharmacists' dynamic role
in health care allows their knowledge and services to be
more accessible to patients.
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